Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 3/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370217 | 0.81 | ADORA3 (0.34) | ADORA3ADORA2AADORA1HRH4MAPK1 | |
| SCHEMBL350535 | 0.80 | SYK (0.41) | GAAMAPTXBP1MAPK1HTT | |
| SCHEMBL352799 | 0.79 | JAK2 (0.39) | ADORA3ADORA2AADORA1HRH4MAPT | |
| SCHEMBL351556 | 0.79 | ADORA2A (0.37) | ADORA3ADORA2AADORA1MAPK1HTT | |
| SCHEMBL352615 | 0.76 | PDE9A (0.40) | ADORA3ADORA2AADORA1MAPTHTT | |
| SCHEMBL350165 | 0.75 | TNNI3K (0.38) | ADORA3ADORA2AADORA1CDK6GPR183 | |
| SCHEMBL1305373 | 0.74 | INSR (0.43) | — | |
| SCHEMBL351991 | 0.74 | ALDH1A1 (0.35) | ADORA3ADORA2AADORA1GPR183SYK | |
| SCHEMBL4414871 | 0.74 | MAPT (0.45) | GAAMAPTXBP1MAPK1HTT | |
| SCHEMBL351077 | 0.74 | SYK (0.42) | KDRSYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | claimed |
| EP-1960372-A1 | KINASE INHIBITORS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | ADORA3 3723/4885ADORA2A 3008/4885ADORA1 4194/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | ADORA3 3723/4885ADORA2A 3008/4885ADORA1 4194/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | ADORA3 3029/4885ADORA2A 2362/4885ADORA1 3082/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | ADORA3 3723/4885ADORA2A 3008/4885ADORA1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.